Description

HPV16 E7 (86-93) is a human leukocyte antigen (HLA)-A2.1 restricted HPV16 E7-derived peptide. HPV16 E7 (86-93) is immunogenic in cervical carcinomas[1][2].—COVID-19-immunoregulation–C37H66N8O10S—-[1]Cheng WF, et al. Induction of human papillomavirus type 16-specific immunologic responses in a normal and an human papillomavirus-infected populations. Immunology. 2005 May;115(1):136-49.|[2]Hoffmann TK, et al. T cells specific for HPV16 E7 epitopes in patients with squamous cell carcinoma of the oropharynx. Int J Cancer. 2006 Apr 15;118(8):1984-91.–160212-93-1–815.03—-CC[C@H](C)[C@@H](C(O)=O)NC([C@H]1N(C([C@H](CS)NC([C@H](C(C)C)NC([C@H]([C@@H](C)CC)NC(CNC([C@H](CC(C)C)NC([C@H]([C@H](O)C)N)=O)=O)=O)=O)=O)=O)CCC1)=O–Infection–10 mM in DMSO–HPV—-Anti-infection–Peptides